{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023470","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.532096+00:00","generated_at":"2026-05-22T06:15:20.377764+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Delcath Q1 revenue surges to $19.8M, posts net income of $1.1M vs loss a year ago","bullets":["Total revenue $19.8M (vs $3.1M Q1 2024); HEPZATO KIT sales $18.0M, CHEMOSAT $1.8M.","Net income $1.1M vs net loss of $11.1M in prior-year quarter; gross margin 86%.","Non-GAAP adjusted EBITDA $7.6M vs loss of $7.3M in Q1 2024.","Cash and investments $58.9M, no debt; exercise of Series F warrants added $16.2M.","19 active U.S. centers; FDA cleared IND for phase 2 HEPZATO in metastatic breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023470","json":"https://secwatch.observer/filing/0001628280-25-023470.json","markdown":"https://secwatch.observer/filing/0001628280-25-023470.md","text":"https://secwatch.observer/filing/0001628280-25-023470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828025023470/0001628280-25-023470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828025023470/dcth-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T06:15:20.377764+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}